Reimbursement, Patient Switches Create Entry Point For Vanda’s Fanapt

Launching a "me too" product with a serious safety risk in a crowded field is not an easy task. But with the right profile and the right expectations, Vanda may have found the perfect entry point for its atypical antipsychotic Fanapt (iloperidone)

More from Archive

More from Pink Sheet